Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Patient Advocacy Groups Lend Support to BIOSIM Act

TOP - October 2021 Vol 14, No 6 | Biosimilars - Patient Advocacy, Biosimilars

On July 1, 2021, 28 patient advocacy groups submitted a letter demonstrating their support for H.R. 2815, also known as the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, which aims to increase Medicare reimbursement for health systems that prescribe biosimilars to patients. The legislation was introduced on April 22, 2021, with the purpose of increasing Medicare payments for biosimilars for a 5-year period.

The letter endorses the act’s mechanism of temporarily increasing reimbursement for biosimilars from average sales price (ASP) plus 6% to ASP plus 8% where the biosimilar price is lower than the reference product price. The patient advocacy groups, which include the 60 Plus Association, the Allergy & Asthma Network, CancerCare, and the Rheumatology Nurses Society, view the act as a way of fixing the “misaligned financial incentives within the Medicare program [that] continue to encourage the use of high-cost brand biologics even when a lower-cost biosimilar medicine is available.”1

In addition, the patient advocacy groups wrote1:

“According to a recent analysis, women, seniors, and low-income individuals are expected to benefit most from increased access to biosimilars, as they are predominantly impacted by the conditions currently treated by higher-cost biologics for which biosimilar competition can reduce costs. However, despite average cost savings of 30%, biosimilar adoption continues to trail expectations.”

The letter comes after the Biosimilars Forum and the Biosimilars Council also expressed their endorsement of the act.

“Biosimilar medicines hold enormous potential to lower the cost of prescription drugs but face significant barriers to adoption. Congressional action on innovative solutions, like the BIOSIM Act, is critical to reducing costs and improving patient access to biosimilars in the U.S.,” the advocacy groups stated.1

Reference

  1. 60 Plus Association, Advocacy & Awareness for Immune Disorders Association, Allergy & Asthma Network, et al. Joint letter to Congressman Schrader and Congressman Kinzinger. July 1, 2021. https://biosimilarsforum.org/wp-content/uploads/letter_of_support_for_the_biosim_act.pdf. Accessed October 20, 2021.
Related Items
HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use
Steven Selde
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in Biosimilars
Survey of Oncologists Reveals Ongoing Misconceptions and Concerns Regarding Biosimilars
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium, Biosimilars
Latest AAM Report Shows Generic and Biosimilar Drugs Saved US Healthcare System $338 Million in 2020
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Value-Based Care, Biosimilars
Addressing and Overcoming Challenges in the Use of Biosimilars
Dawn Holcombe, MBA, FACMPE, ACHE
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Best Practices, Biosimilars
Considerations for Integrating Biosimilars into Your Practice
Kashyap Patel, MD
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Perspective, Biosimilars
Noteworthy Numbers: Biosimilars and Value-Based Care
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Noteworthy Numbers, Biosimilars
From The Editors: October 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in From the Editors, Biosimilars
Analysis of Healthcare Claims Shows Encouraging Trend in the Use of Trastuzumab Biosimilars
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium, Biosimilars
Pharmacist-Driven Intervention Leads to Significant Increase in Biosimilar Adoption
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium, Biosimilars
Multidisciplinary Team Approach Leads to Rapid Biosimilar Adoption in Community Oncology Practice
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Best Practices, Biosimilars
Last modified: November 8, 2021